US4708713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and system for removing immunosuppressive components from the blood of mammals
Assignee: Biopheresis Technologies Inc
•
Filing: 1984-11-16
•
Granted: 1987-11-24
•
Expires: 2004-11-16
Abstract
Abstract The invention relates to a method and system for extracorporeally treating the blood of a patient having diseased tissue or a condition, such as cancer, which results from or depends upon a dysfunction of the patient's immune system. In accordance with the invention, blood is withdrawn from the pateint, a low molecular weight fraction of the blood containing immunosuppressive components which retard or prevent immune system responses is selectively separated from the withdrawn blood, preferably by means of an ultrafilter, and treated blood is returned to the patient to initiate an immune response.
Inventors
- 👤 M. Rigdon Lentz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 05:46
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/34; A61M1/3403; A61M1/342; A61M1/3441; A61M1/3448; A61M1/3472; A61M1/3482; A61M1/36; A61M1/3621; A61M1/3623; A61M2205/00; A61M2205/33; A61M2205/3331; A61M2205/3344
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
154 words
A method of extracorporeally treating a mammalian patient having a dysfunction of the immune system thereof wherein immunosuppressive components having molecular weights less than 200,000 Daltons retard or prevent immune system response, the method including a plurality of treatments with each treatment comprising: (a) withdrawing whole blood comprising a cellular fraction and a plasma fraction from a patient having such a dysfunction; (b) selectively separating from the withdrawn whole blood components of the plasma fraction with molecular weights less than 200,000 Daltons including the immunosuppressive components which retard or prevent immune system response to the immune system dysfunction; and (c) returning to the patient whole blood from which the components of the plasma fraction have been separated; and (d) continuing the treatment until the concentration of immunosuppressive components with molecular weights less than 200,000 Daltons in the extracellular fluid of the patient are reduced to a level sufficient to initiate an immune system response.
Claim 2
Independent Claim
154 words
A method of extracorporeally treating a mammalian patient having a dysfunction of the immune system thereof wherein immunosuppressive components having molecular weights less than 200,000 Daltons retard or prevent immune system response, the method including a plurality of treatments with each treatment comprising: (a) withdrawing whole blood comprising a cellular fraction and a plasma fraction from a patient having such a dysfunction; (b) selectively separating from the withdrawn whole blood components of the plasma fraction with molecular weights less than 200,000 Daltons including the immunosuppressive components which retard or prevent immune system response to the immune system dysfunction; and (c) returning to the patient whole blood from which the components of the plasma fraction have been separated; and (d) continuing the treatment until the concentration of immunosuppressive components with molecular weights less than 200,000 Daltons in the extracellular fluid of the patient are reduced to a level sufficient to initiate an immune system response.
Claim 3
Dependent Claim
28 words
The method of claim 1 wherein the blood fraction is selectively separated from the blood without separating high molecular weight components including blood cells and platelets from plasma.
Claim 4
Dependent Claim
33 words
The method of claim 1 wherein the blood fraction is selectively separated from the blood by passing the withdrawn blood through an ultrafilter to remove therefrom the blood fraction as ultrafiltrate or permeate.
Claim 5
Dependent Claim
47 words
The method of claim 1 wherein components of the plasma fraction with molecular weights less than about 200,000 Daltons are selectively separated from the withdrawn whole blood by ultrafiltration with an ultrafiltration medium having an effective pore size from about 0.03 to less than about 0.10 micron.
Claim 6
Dependent Claim
33 words
The method of claim 4 wherein the blood fraction is selectively separated from the blood by ultrafiltration with an ultrafiltration medium having an effective pore size from about 0.03 to about 0.07 micron.
Claim 7
Dependent Claim
34 words
The method of claim 1 wherein liquid is returned to the patient from which the blood is withdrawn to replace the liquid lost from the withdrawn blood when the plasma components are separated therefrom.
Claim 8
Dependent Claim
51 words
The method of claim 6 wherein at least one member of the group consisting of nutrients, vitamins and salts is added to the liquid returned to the mammal from which the blood is withdrawn to replace those which are lost from the withdrawn blood when the plasma fraction is separated therefrom.
Claim 9
Independent Claim
178 words
The method of treating a mammalian patient with cancer or other neoplastic tissue, the growth or continuation of which results from or depends upon a dysfunction of the immune system thereof wherein immunosuppressive components having molecular weights less then 200,000 Daltons retard or prevent immune system response, the method including a plurality of treatments with each treatment comprising: (a) withdrawing whole blood which includes a cellular fraction and a plasma fraction from a patient with cancer or other neoplastic tissue; (b) selectively separating from the withdrawn whole blood components of the plasma fraction having molecular weights less than 200,000 Daltons including the immunosuppressive components which retard or prevent immune system response to cancer or other neoplastic tissue; (c) returning to the patient whole blood from which the components of the plasma fraction have been removed; and (d) the treatment continuing until the concentration of immunosuppressive components with molecular weights less than 200,000 Daltons in the extracellular fluid of the patient is reduced to a level sufficient to initiate an immune system response to the cancer or neoplastic tissue.
Claim 10
Independent Claim
178 words
The method of treating a mammalian patient with cancer or other neoplastic tissue, the growth or continuation of which results from or depends upon a dysfunction of the immune system thereof wherein immunosuppressive components having molecular weights less then 200,000 Daltons retard or prevent immune system response, the method including a plurality of treatments with each treatment comprising: (a) withdrawing whole blood which includes a cellular fraction and a plasma fraction from a patient with cancer or other neoplastic tissue; (b) selectively separating from the withdrawn whole blood components of the plasma fraction having molecular weights less than 200,000 Daltons including the immunosuppressive components which retard or prevent immune system response to cancer or other neoplastic tissue; (c) returning to the patient whole blood from which the components of the plasma fraction have been removed; and (d) the treatment continuing until the concentration of immunosuppressive components with molecular weights less than 200,000 Daltons in the extracellular fluid of the patient is reduced to a level sufficient to initiate an immune system response to the cancer or neoplastic tissue.
Claim 11
Dependent Claim
39 words
The method of claim 8 wherein the treatment is repeated on a plurality of occasions until the cancer or neoplastic tissue has been essentially destroyed or until the cancer or neoplastic tissue can be surgically removed or otherwise treated.
Claim 12
Dependent Claim
35 words
The method of claim 8 wherein blood fraction is selectively separated from the withdrawn blood by ultrafiltration with an ultrafilter medium having an effective pore size from about 0.03 to less than about 0.10 micron.
Claim 13
Dependent Claim
34 words
The method of claim 8 wherein liquid is returned to the patient from which the blood is withdrawn to replace the liquid lost from the withdrawn blood when the plasma components are separated therefrom.
Claim 14
Dependent Claim
51 words
The method of claim 11 wherein at least one member of the group consisting of nutrients, vitamins and salts is added to the liquid returned to the patient from which the blood was withdrawn to replace those which are lost from the withdrawn blood when the plasma fraction is separated therefrom.
Claim 15
Dependent Claim
28 words
The method of claim 12 wherein the lost nutrients, vitamins and salts are returned in a volume of liquid essentially equivalent to the volume of blood fraction separated.
References Cited (Backward Citations)
US31688A
Cited
US4116589A
Cited
US4191182A
Cited
USRE31688E
Cited
WO1979001121A1
Cited
US4350156A
Cited
EP0076665A2
Cited
DE3302384A1
Cited
GB2136314A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-23 | 1991-05-25 | 1991-11-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-23 | 1995-05-25 | 1995-11-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-23 | 1999-05-25 | 1999-11-24 | $7700.00 | Window Closed / Lapsed |